Axon Therapies is addressing a root cause of heart failure with their frontline therapy by selectively ablating the neural pathway carrying information from the chronically hyperactive sympathetic nervous system (SNS) in order to restore volume balance, stop disease progression and improve symptoms
External link for Axon Therapies Inc.
2326 Walsh Ave
Santa Clara, California 95051, US
Axon Therapies Inc. reposted this
Sitting on the Board of Axon Therapies Inc., now an Earlybird Heath portfolio company, I'm proud to see them presenting this groundbreaking technology at the Georgia Medtech Summit today. Well done Daniel Burkhoff! Cc: Zoar Engelman, Earlybird Venture Capital #HeartFailure #MedTech #EarlybirdHealth
Grateful to Dr. Daniel Burkhoff for representing Axon Therapies at the Georgia MedTech Innovation Summit. Thank you for sharing your expertise with the broader innovation community. Marat Fudim Liviu Klein #MedTech #HeartFailure #GeorgiaMedTechSummit #ClinicalAccelerator #AxonTherapies
We’re proud to announce that Axon Therapies has closed an oversubscribed $32M round, co-led by Earlybird Venture Capital and SANTÉ, with participation from Deerfield Management, CD Capital, and KOFA Healthcare. This investment will advance clinical studies of our Satera™ Ablation System, an implant-free, catheter-based therapy that address a key driver of heart failure by greater splanchnic nerve modulation. We’re also excited to welcome Zoar Engelman as Chief Executive Officer and to expand our global presence with a new European headquarters in the UK. https://lnkd.in/e-DfFF2x #HeartFailure #MedTech